ABOS · Acumen Pharmaceuticals, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, management has concluded that substantial doubt exists regarding our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 12, 2026TL;DR. Acumen reported a narrower Q2 net loss and reduced R&D spending while advancing toward the late-2026 ALTITUDE-AD Phase 2 topline readout for sabirnetug in early Alzheimer's, and nominated two Enhanced Brain Delivery candidates with lead IND targeted for mid-2027; cash of $110.2M is stated to fund operations only into early 2027.
- + R&D expenses fell year-over-year in Q2 2026.
- + Two Enhanced Brain Delivery candidates were nominated, with lead IND targeted for mid-2027.
- − Cash runway is stated to extend only into early 2027, ahead of the mid-2027 targeted EBD IND.
- − Company remains unprofitable with a Q2 2026 loss from operations of $32.6M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABOS
this stock
Acumen Pharmaceuticals, Inc.
|
$159.46M | -3.3% | — | — | 3.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABOS | -8.9% | -34.0% | -18.7% | -8.1% | -3.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -8.7% | -33.5% | -30.9% | -9.0% | -16.2% |